Crossref


1. A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran

- Mojtaba Jafari

- Parisa Mehdizadeh

- Khosro Keshavarz

- Ehsan Teymourzadeh

- Mohammad Ali Abyazi

- Seyed Moayed Alavian

- Alijanpour Pouria

2. Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study

- Mojtaba Jafari

- Parisa Mehdizadeh

- Khosro Keshavarz

- Ehsan Teymourzadeh

- Mohammad Ali Abyazi

- Parsa Gholamreza Shirazi